ICM
AVIR icon

Irenic Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Irenic Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-301,699
Closed -$1.62M – 50
2026
Q1 		$1.62M Buy
+301,699
New +$1.39M 0.11% 42

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Irenic Capital Management's AVIR Position: Q2 2026 in Review

Irenic Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 301,699 shares — an estimated $1.62M sold.

Irenic Capital Management first reported a position in AVIR in Q1 2026 and held it in 1 quarter. The position peaked at $1.62M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Irenic Capital Management reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Irenic Capital Management sold 301,699 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.62M.
  • Irenic Capital Management first reported a position in Atea Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Irenic Capital Management's Atea Pharmaceuticals position peaked at $1.62M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Irenic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.